Company Description
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions.
It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.
It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 25, 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 610 |
| CEO | Derek J. Maetzold |
Contact Details
Address: 505 S Friendswood Drive, Suite 401 Friendswood, Texas 77546 United States | |
| Phone | 866-788-9007 |
| Website | castlebiosciences.com |
Stock Details
| Ticker Symbol | CSTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001447362 |
| CUSIP Number | 14843C105 |
| ISIN Number | US14843C1053 |
| Employer ID | 77-0701774 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Derek J. Maetzold | Founder, Chief Executive Officer, President and Director |
| Frank Stokes | Chief Financial Officer and Treasurer |
| Kristen M. Oelschlager R.N. | Chief Operating Officer |
| Tobin W. Juvenal | Chief Commercial Officer |
| Camilla Zuckero | Vice President of Investor Relations and Corporate Affairs |
| Alice Bahner Izzo | Senior Vice President of Marketing |
| Kevin Doman | Vice President of Sales |
| Keli Greenberg | Vice President of Human Resources and Executive Director of Human Resources |
| Dr. Robert W. Cook Ph.D. | Senior Vice President of Research and Development |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 144 | Filing |
| Apr 10, 2024 | ARS | Filing |
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | 144 | Filing |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 144 | Filing |
| Mar 5, 2024 | 144 | Filing |
| Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | S-3 | Registration statement under Securities Act of 1933 |